

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

IN RE: NEXIUM (ESOMEPRAZOLE)
ANTITRUST LITIGATION)
) MDL NO. 2409
) CIVIL ACTION NO.
) 12-MD-02409-WGY
)

JURY VERDICT

1. Did AstraZeneca exercise market power within the relevant market?

no yes

2. Did the settlement of the AstraZeneca-Ranbaxy patent litigation include a large and unjustified payment by AstraZeneca to Ranbaxy?

no yes

3. Was AstraZeneca's Nexium settlement with Ranbaxy unreasonably anticompetitive, i.e. did the anticompetitive effects of that settlement outweigh any pro-competitive justifications?

no yes

4. Had it not been for the unreasonably anticompetitive settlement, would AstraZeneca have agreed with Ranbaxy that Ranbaxy might launch a generic version of Nexium before May 27, 2014?

no yes

5. If so, what would be the effective date of such a license?

, 20

- 6.a. Had it not been for the unreasonably anticompetitive settlement, would Ranbaxy have agreed with Teva to launch a generic version of Nexium before May 27, 2014?

no yes

6.b. If so, when would Teva have launched?

_____ , 20 _____

7. If a generic version of Nexium had come to market,
would an authorized generic have entered at or about
the same time?

_____ no _____ yes

Date: 12/5/14

mHamilton
Forelady